Codiak Biosciences outlines a new focus for its exosome platform in $86M IPO filing
Venture raises from marquee investors? Check. Collaboration deal? Check. Clinical trial timeline? Check. For its next step, Codiak Biosciences is headed for an IPO. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.